{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:32:56Z","timestamp":1763533976684},"reference-count":31,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.3892\/or.2016.5226","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T09:30:33Z","timestamp":1478511033000},"page":"547-554","source":"Crossref","is-referenced-by-count":5,"title":["Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia"],"prefix":"10.3892","volume":"37","author":[{"given":"Jana","family":"\u0160mahelov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Ka\u0161t\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina Machov\u00e1","family":"Pol\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Klamov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Zemanov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Tachezy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Ham\u0161\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"\u0160mahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"key20180107224951_b1-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"key20180107224951_b2-or-37-01-0547","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"key20180107224951_b3-or-37-01-0547","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.21096","article-title":"Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors","volume":"83","author":"Ou","year":"2008","journal-title":"Am J Hematol"},{"key":"key20180107224951_b4-or-37-01-0547","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","article-title":"Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34\u2212 cell population with intrinsic resistance to imatinib","volume":"114","author":"Lemoli","year":"2009","journal-title":"Blood"},{"key":"key20180107224951_b5-or-37-01-0547","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"key20180107224951_b6-or-37-01-0547","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107224951_b7-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/sj.leu.2403779","article-title":"Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability","volume":"19","author":"Giehl","year":"2005","journal-title":"Leukemia"},{"key":"key20180107224951_b8-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.exphem.2006.07.009","article-title":"Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules","volume":"34","author":"Schmitt","year":"2006","journal-title":"Exp Hematol"},{"key":"key20180107224951_b9-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0301-472X(02)00874-3","article-title":"Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia","volume":"30","author":"Greiner","year":"2002","journal-title":"Exp Hematol"},{"key":"key20180107224951_b10-or-37-01-0547","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/leu.2010.29","article-title":"Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia","volume":"24","author":"Giannopoulos","year":"2010","journal-title":"Leukemia"},{"key":"key20180107224951_b11-or-37-01-0547","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","article-title":"Aurora-A kinase: A novel target of cellular immunotherapy for leukemia","volume":"113","author":"Ochi","year":"2009","journal-title":"Blood"},{"key":"key20180107224951_b12-or-37-01-0547","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/med.20203","article-title":"Biology of Aurora A kinase: Implications in cancer manifestation and therapy","volume":"31","author":"Karthigeyan","year":"2011","journal-title":"Med Res Rev"},{"key":"key20180107224951_b13-or-37-01-0547","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.drudis.2011.05.002","article-title":"PLK1 as an oncology target: Current status and future potential","volume":"16","author":"McInnes","year":"2011","journal-title":"Drug Discov Today"},{"key":"key20180107224951_b14-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-09-2181","article-title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: Overriding imatinib resistance with the Plk1 inhibitor BI 2536","volume":"70","author":"Gleixner","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107224951_b15-or-37-01-0547","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1073\/pnas.0801610105","article-title":"Overexpression of Separase induces aneuploidy and mammary tumorigenesis","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107224951_b16-or-37-01-0547","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-08-2454","article-title":"Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers","volume":"15","author":"Meyer","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107224951_b17-or-37-01-0547","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2105-11-150","article-title":"Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomes","volume":"11","author":"Rouam","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"key20180107224951_b18-or-37-01-0547","doi-asserted-by":"crossref","first-page":"e42863","DOI":"10.1371\/journal.pone.0042863","article-title":"The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib","volume":"7","author":"Haa\u00df","year":"2012","journal-title":"PLoS One"},{"key":"key20180107224951_b19-or-37-01-0547","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.leukres.2009.11.029","article-title":"Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes","volume":"34","author":"Tamura","year":"2010","journal-title":"Leuk Res"},{"key":"key20180107224951_b20-or-37-01-0547","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"key20180107224951_b21-or-37-01-0547","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exphem.2009.10.003","article-title":"Constant BCR-ABL transcript level \u2265=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis","volume":"38","author":"Pol\u00e1kov\u00e1","year":"2010","journal-title":"Exp Hematol"},{"key":"key20180107224951_b22-or-37-01-0547","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180107224951_b23-or-37-01-0547","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5483\/BMBRep.2011.44.4.279","article-title":"Improved recovery of active GST-fusion proteins from insoluble aggregates: Solubilization and purification conditions using PKM2 and HtrA2 as model proteins","volume":"44","author":"Park","year":"2011","journal-title":"BMB Rep"},{"key":"key20180107224951_b24-or-37-01-0547","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-1759(01)00376-3","article-title":"A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: Validation for HPV serology","volume":"253","author":"Sehr","year":"2001","journal-title":"J Immunol Methods"},{"key":"key20180107224951_b25-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00262-011-1126-z","article-title":"Antigens in chronic myeloid leukemia: Implications for vaccine development","volume":"60","author":"Smahel","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"key20180107224951_b26-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2003-11-4079","article-title":"RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma","volume":"104","author":"Maxwell","year":"2004","journal-title":"Blood"},{"key":"key20180107224951_b27-or-37-01-0547","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/leu.2008.338","article-title":"The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia","volume":"23","author":"Giannopoulos","year":"2009","journal-title":"Leukemia"},{"key":"key20180107224951_b28-or-37-01-0547","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/ijc.28434","article-title":"Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling","volume":"134","author":"Yang","year":"2014","journal-title":"Int J Cancer"},{"key":"key20180107224951_b29-or-37-01-0547","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.2174\/092986711798184271","article-title":"Effects of BCR-ABL inhibitors on anti-tumor immunity","volume":"18","author":"Krusch","year":"2011","journal-title":"Curr Med Chem"},{"key":"key20180107224951_b30-or-37-01-0547","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107224951_b31-or-37-01-0547","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1038\/bcj.2013.44","article-title":"Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562\/GVAX immunotherapy","volume":"3","author":"Qin","year":"2013","journal-title":"Blood Cancer J"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2016.5226\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T16:40:58Z","timestamp":1657644058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2016.5226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,11,7]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.3892\/or.2016.5226"],"URL":"https:\/\/doi.org\/10.3892\/or.2016.5226","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,7]]}}}